Overview

Ahmed focuses his practice in intellectual property providing counsel and support in connection with patent and trademark enforcement and defense. His practice includes Hatch-Waxman Paragraph IV disputes and patent troll issues. Ahmed’s transactional practice focuses on negotiating and drafting licensing, commercial supply, clinical trial, and distribution agreements. Ahmed has also counseled start-up and early stage companies looking to grow their business while avoiding costly litigation.

A curious and highly analytical attorney with substantive in-house experience, Ahmed is known for his ability to understand complex technologies and develop effective litigation strategies in view of his clients’ business realities.

Prior to joining Schiff Hardin, Ahmed was in-house counsel for a publicly traded medical device company. In this role, he helped to develop, protect and capitalize on the strategic development of an international intellectual property portfolio and managed multiple litigations. Ahmed also gained extensive experience negotiating and preparing licensing, commercial supply and co-promotion agreements, and importantly gained first-hand knowledge of the business realities that inform business and legal decisions.

  • Experience

    Commercial Litigation

    • Successfully represented YuppTV USA, Inc., one of the world’s largest internet-based TV and On-demand service providers for South Asian content, in obtaining emergency relief as a third party intervenor in a dispute between Dish Network LLC, et al. and  Asia TV USA Ltd. in the United States District Court for the Southern District of New York. The temporary restraining order barred Asia TV USA Ltd. from terminating its Distribution Agreement or otherwise ceasing transmission of its television channels to our client.

    Patent Litigation

    • Successfully represented Fresenius Kabi USA, LLC in obtaining a rare preliminary injunction in federal district court. The injunction barred our client’s competitor from launching a generic version of its patented formulation of levothyroxine, an injectable thyroid hormone. The District Court for the District of New Jersey granted the injunction on the basis that our client was likely to win its patent lawsuit against its competitor.
    • Managed litigation strategy for plaintiff in a declaratory judgment action seeking a preliminary injunction as in-house counsel.
    • Managed inter partes review strategies as in-house counsel at medical device company.

    Transactions

    As in-house counsel, Ahmed’s representative experience included:

    • Negotiating and drafting U.S. promotion agreement out licensing drug product for marketing in South Korea on an exclusive basis.
    • Negotiating and drafting license agreement out-licensing drug technology to develop over the counter drug product on exclusive basis for North America.
    • Negotiating and drafting License, Supply, and Distribution Agreement with generic company out licensing device technology for a drug-device combination product in the United States.
  • Credentials

    Education

    • Temple University Beasley School of Law, J.D., 2008
      Temple Political and Civil Rights Law Review, Member
      Moot Court Honor Society, Treasurer
    • Hunter College, B.A., Economics, 2004

    Bar Admissions

    • New York
    • New Jersey
    • Pennsylvania
    • U.S. Court of Appeals for the Federal Circuit
    • U.S. District Court for the District of New Jersey

        Professional Memberships

        • American Bar Association, Intellectual Property Law Section
        • American Intellectual Property Law Association
      • Insights

        TITLE
        News Release

        Schiff Counsels CNS Pharmaceuticals on $11.5M Public Offering

        Schiff Hardin advised CNS Pharmaceuticals, Inc. in connection with its public offering of 5,750,000 shares of common stock and 2,875,000 warrants to purchase common stock for gross proceeds of $11.5 million.

        News Release

        Schiff Advises Moleculin Biotech, Inc. on its $78M Public Offering

        Schiff Hardin LLP advised Moleculin Biotech, Inc. in connection with its public offering of 16,414,736 shares of common stock for gross proceeds of approximately $78 million.

        News Release

        Schiff Hardin Advises Altaris in Acquisition of 3M’s Drug Delivery Business

        Schiff Hardin LLP represented Altaris Capital Partners LLC, a private investment firm focused on the healthcare industry, in its $650 million acquisition of substantially all of Kindeva Drug Delivery from 3M Company.

        News Release

        Schiff Hardin Wins Patent Infringement Appeal

        Schiff Hardin won an appeal for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., showing a formulation patent claim is invalid and helping generics further develop the “inherent obviousness” case law.

        News Release

        Leadership Council on Legal Diversity Selects Three Schiff Attorneys for 2019 Leadership Programs

        Schiff Hardin is pleased to announce that three attorneys have been selected for the Leadership Council on Legal Diversity’s (LCLD) 2019 leadership programs.

        News Release

        Schiff Hardin Secures Patent Infringement Win

        Schiff Hardin successfully secured a favorable outcome for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., which paves the way for Fresenius to market a new generic drug.

        Alert

        SCOTUS Decision Reaffirms Free Speech in Disparaging Trademarks

        The U.S. Supreme Court’s Lee v. Tam decision struck down a provision of the federal trademark law.

        Alert

        Pharma team scores rare preliminary injunction

        Schiff Hardin’s pharma and life sciences patent litigation team, lead by partner Imron T. Aly, recently secured a preliminary injunction in federal court.

      • Citizenship

        Pro Bono Activities

        • Ahmed represents indigent clients seeking asylum in the United States